Sulaquin, Gina F.
HRN: 21-53-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/16/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/16/2022
07/22/2022
19MG
Ivt
Q8 For 7 Days
Pertussis, Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaBloodstream Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes